Results 121 to 130 of about 52,728 (165)
Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial. [PDF]
EBioMedicineViermyr HK, Tonby K, Ponzi E, Trouillet-Assant S, Poissy J, Arribas JR, Dyon-Tafani V, Bouscambert-Duchamp M, Assoumou L, Halvorsen B, Tekin NB, Diallo A, De Gastines L, Munthe LA, Murphy SL, Ueland T, Michelsen AE, Lund-Johansen F, Aukrust P, Mootien J, Dervieux B, Zerbib Y, Richard JC, Prével R, Malvy D, Timsit JF, Peiffer-Smadja N, Roux D, Piroth L, Ait-Oufella H, Vieira C, Dalgard O, Heggelund L, Müller KE, Møller JH, Kildal AB, Skogen V, Aballi S, Sjøberg Øgaard JD, Dyrhol-Riise AM, Tveita A, Alirezaylavasani A, Costagliola D, Yazdanpanah Y, Olsen IC, Dahl TB, Kared H, Holten AR, Trøseid M. +48 moreeuropepmc +1 more sourcePostoperative SBRT and Severe Late Toxic Effects in Early-Stage Oropharyngeal and Oral Cavity Cancers: The STEREOPOSTOP-GORTEC 2017-03 Nonrandomized Clinical Trial.
JAMA Netw OpenBiau J, Sun X, Liem X, Faivre JC, Eker E, Blanchard P, Tao Y, Doré M, Maingon P, Vulquin N, Alfonsi M, Thureau S, Huguet F, Racadot S, Thivat E, Molnar I, Boisselier P, Guihard S, Gallocher O, Dupin C, Batard S, Bourhis J, Lapeyre M. +22 moreeuropepmc +1 more sourcesST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial. [PDF]
Sci RepSmadja DM, Massonnaud CR, Philippe A, Rosa M, Luneau S, Rauch A, Peiffer-Smadja N, Gagneux-Brunon A, Poissy J, Gruest M, Ung A, Pourcher V, Raffi F, Piroth L, Bouiller K, Esperou H, Delmas C, Belhadi D, Diallo A, Saillard J, Dechanet A, Mercier N, Dupont A, Lescure FX, Goehringer F, Jaureguiberry S, Danion F, Tolsma V, Cabie A, Courjon J, Leroy S, Mootien J, Mourvillier B, Gallien S, Lanoix JP, Botelho-Nevers E, Wallet F, Richard JC, Reuter J, Gaymard A, Greil R, Martin-Blondel G, Andrejak C, Yazdanpanah Y, Burdet C, Diehl JL, Hites M, Ader F, Susen S, Mentré F, Dupont A, Discovery Study Group. +51 moreeuropepmc +1 more sourcePredictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study. [PDF]
OncologistEvrard C, Pelras A, Rivet S, Bachet JB, Dubreuil O, Pointet AL, Taieb J, Lahlou W, Portal A, Lepère C, Lecomte T, Chautard R, Williet N, Phelip JM, Coutzac C, Soularue E, Marthey L, Abdallah R, Thirot Bidault A, Artru P, Desrame J, Le Roy B, Jary M, Hammel P, Trouilloud I, Lourenco N, Hautefeuille V, Dahan L, Pernot S, Béchade D, Pozet A, Bonnetain F, Locher C, Dréanic J, Coriat R, Tchoundjeu B, Foucher Y, Tougeron D. +37 moreeuropepmc +1 more sourceAddressing the Global Challenge of Nitrous Oxide Misuse Through a Multidisciplinary Approach: Example of the PROTOSIDE Network. [PDF]
ToxicsGrzych G, Diesnis R, Dupré T, Niguet JP, Gernez E, Denimal D, Deheul S, Guichard JC, Scliffet D, Mégarbane B, Redonnet-Vernhet I, Boucher A, Bennis A, Karila L, Cavalier E, Rolland B, Riou C, Bossaert C, Chauvin A, multidisciplinary network PROTOSIDE. +19 moreeuropepmc +1 more sourceSubstance use disorder of equimolar oxygen-nitrous oxide mixture in French sickle-cell patients: results of the PHEDRE study. [PDF]
Orphanet J Rare DisGérardin M, Rousselet M, Couec ML, Masseau A, PHEDRE Group, Aquizerate A, Authier N, Deheul S, Roussin A, Micallef J, Djezzar S, French Addictovigilance Network (FAN), Feuillet F, Jolliet P, Grall-Bronnec M, Victorri-Vigneau C. +15 moreeuropepmc +1 more sourceGut microbial dysbiosis associated to diarrheic irritable bowel syndrome can be efficiently simulated in the Mucosal ARtificial COLon (M-ARCOL). [PDF]
BioengineeredUriot O, Deschamps C, Scanzi J, Brun M, Kerckhove N, Dualé C, Fournier E, Durif C, Denis S, Dapoigny M, Langella P, Alric M, Etienne-Mesmin L, Stéphanie BD. +13 moreeuropepmc +1 more sourceSome of the next articles are maybe not open access.Related searches:
Anti-infectious treatment duration: The SPILF and GPIP French guidelines and recommendations.
Infectious Diseases Now, 2021 a Infectiologie transversale, CHU Cochin, AP–HP, 75014 Paris, France b Maladies infectieuses et tropicales, CHG, 24000 Périgueux, France c Équipe Mobile d’Infectiologie, Hôpital Joseph-Ducuing, Clinique Pasteur, 31300 Toulouse, France d Maladies ...R. Gauzit, B. Castan, E. Bonnet, J. Bru, R. Cohen, S. Diamantis, A. Faye, H. Hitoto, N. Issa, D. Lebeaux, P. Lesprit, L. Maulin, D. Poitrenaud, J. Raymond, C. Strady, E. Varon, R. Verdon, F. Vuotto, Y. Welker, J. Stahl +19 moresemanticscholar +1 more sourceAdverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg)
American Journal of Gastroenterology, 2021 INTRODUCTION: The safety of Helicobacter pylori eradication treatments and to what extent adverse events (AEs) influence therapeutic compliance in clinical practice are hardly known.O. Nyssen, Á. Pérez‐Aísa, B. Tepeš, M. Castro-Fernández, J. Kupčinskas, L. Jonaitis, L. Bujanda, A. Lucendo, N. B. Jurecic, J. Pérez-Lasala, O. Shvets, G. Fadeenko, J. Huguet, Zdenki Kikec, D. Bordin, I. Voynovan, M. Leja, J. Machado, M. Areia, L. Fernández-Salazar, L. Rodrigo, S. Alekseenko, J. Barrio, J. Ortuño, M. Perona, L. Vologzhanina, P. M. Romero, O. Zaytsev, T. Rokkas, S. Georgopoulos, R. Pellicano, G. Buzás, I. Modolell, B. G. Gómez Rodríguez, I. Şimşek, Cem Şimşek, M. Lafuente, T. Ilchishina, J. G. Camarero, M. Dominguez-Cajal, Vassiliki Ntouli, N. Dekhnich, P. Phull, Ó. Núñez, F. Lerang, M. Venerito, F. Héluwaert, A. Tonkić, M. Caldas, I. Puig, F. Mégraud, C. O'Morain, J. Gisbert +52 moresemanticscholar +1 more source
